Physician profile
David C Dosik
NPI 1770534653
$8,741.83
in general payments reported to CMS, 2019-2025
66 companies · $1,469 in 2025
The $1,469 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,884 · 2020: $936 · 2021: $866 · 2022: $1,119 · 2023: $1,331 · 2024: $1,136 · 2025: $1,469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,706 · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,705.75 |
| Education | $230.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $790.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $635.78 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $576.77 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $435.99 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $411.54 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Pfizer INC. | $399.91 | 2019-2025 | |
| Celgene Corporation | $342.63 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Janssen Biotech, INC. | $294.58 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Alexion Pharmaceuticals, INC. | $268.38 | 2019 | |
| Eisai INC. | $263.44 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $256.19 | 2019-2025 | Provenge |
| Gilead Sciences, INC. | $245.38 | 2019-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $232.02 | 2019-2024 | Calquence |
| Seagen INC. | $228.12 | 2020-2023 | Tukysa, Adcetris |
| Astellas Pharma US INC | $224.33 | 2019-2024 | Xtandi |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $195.20 | 2020-2025 | |
| Glaxosmithkline, LLC. | $178.22 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Celltrion USA INC. | $176.55 | 2023-2025 | Vegzelma |
| Pharmacyclics LLC, An Abbvie Company | $174.32 | 2019-2023 | Imbruvica |
| Amgen INC. | $163.68 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Genentech USA, INC. | $162.78 | 2019-2023 | Perjeta, Phesgo |
| Abbvie INC. | $145.25 | 2024-2025 | |
| Taiho Oncology, INC. | $141.23 | 2022-2025 | |
| Exelixis INC. | $128.07 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $123.10 | 2019-2022 | |
| Kite Pharma, INC. | $108.50 | 2020-2024 | Yescarta |
| Array Biopharma INC | $103.13 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Coherus Oncology, INC. | $99.56 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $96.29 | 2020-2023 | Xpovio |
| Puma Biotechnology, INC. | $93.17 | 2020-2025 | |
| Foundation Medicine, INC. | $82.20 | 2020-2023 | Foundationone Cdx |
| Ipsen Biopharmaceuticals, INC | $67.53 | 2024 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $65.17 | 2019-2020 | |
| Springworks Therapeutics, INC. | $50.65 | 2024-2025 | Gomekli, Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.13 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.02 | 2020-2025 | Fruzaqla |
| Amag Pharmaceuticals, INC. | $41.93 | 2020 | |
| Agios Pharmaceuticals, INC. | $41.59 | 2023-2025 | Pyrukynd |
| Stemline Therapeutics INC. | $37.19 | 2023-2024 | Elzonris, Orserdu |
| Octapharma USA, INC. | $35.07 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
| Dova Pharmaceuticals | $32.09 | 2020 | |
| Beone Medicines USA, INC. | $31.05 | 2025 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $24.06 | 2025 | Tavalisse |
| Mylan Institutional INC. | $23.26 | 2023 | Ogivri, Fulphila |
| Myovant Sciences INC. | $23.09 | 2022 | |
| Cook Medical LLC | $23.02 | 2025 | Zenith Alpha |
| Stryker Corporation | $22.48 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Sobi, INC | $22.14 | 2024 | |
| Shield Therapeutics INC | $21.71 | 2023 | Accrufer |
| Epizyme, INC. | $21.40 | 2022 | |
| Deciphera Pharmaceuticals INC. | $21.38 | 2023 | Qinlock |
| Tolmar, INC. | $21.31 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $21.25 | 2024 | Libtayo |
| Amneal Pharmaceuticals LLC | $19.31 | 2023 | Alymsys |
| Innate Pharma, INC | $19.14 | 2020 | |
| Telix Pharmaceuticals | $18.81 | 2024 | Illuccix |
| Global Blood Therapeutics, INC. | $18.72 | 2021 | |
| Verity Pharmaceuticals INC. | $18.63 | 2024 | Trelstar |
| Mirati Therapeutics, INC. | $18.09 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $17.96 | 2022 | |
| Jazz Pharmaceuticals INC. | $17.28 | 2024 | |
| G1 Therapeutics, INC. | $17.17 | 2022 | |
| Emmaus Medical, INC. | $16.07 | 2024 | Endari |
| Verastem, INC. | $15.57 | 2019 | |
| Tersera Therapeutics LLC | $14.83 | 2023 | Xermelo |
| Immunogen, INC. | $12.71 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dosik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.